First Command Advisory Services Inc. Sells 552 Shares of Johnson & Johnson (NYSE:JNJ)

First Command Advisory Services Inc. reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.7% in the first quarter, according to its most recent filing with the SEC. The fund owned 14,327 shares of the company’s stock after selling 552 shares during the quarter. First Command Advisory Services Inc.’s holdings in Johnson & Johnson were worth $2,376,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC increased its stake in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after purchasing an additional 6,332 shares during the period. Hudson Value Partners LLC increased its stake in Johnson & Johnson by 2.5% in the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company’s stock worth $5,648,000 after purchasing an additional 1,022 shares during the period. Proficio Capital Partners LLC increased its stake in Johnson & Johnson by 22.0% in the fourth quarter. Proficio Capital Partners LLC now owns 19,951 shares of the company’s stock worth $2,885,000 after purchasing an additional 3,594 shares during the period. Creative Financial Designs Inc. ADV increased its stake in Johnson & Johnson by 7.6% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 9,509 shares of the company’s stock worth $1,375,000 after purchasing an additional 668 shares during the period. Finally, Argent Advisors Inc. increased its stake in Johnson & Johnson by 2.1% in the fourth quarter. Argent Advisors Inc. now owns 17,191 shares of the company’s stock worth $2,486,000 after purchasing an additional 354 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on JNJ shares. Barclays reduced their target price on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 17th. Morgan Stanley restated an “underperform” rating on shares of Johnson & Johnson in a research note on Thursday, July 10th. Royal Bank Of Canada restated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research note on Thursday, June 5th. Bank of America cut their price target on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a research note on Thursday, April 10th. Finally, Wall Street Zen upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 21st. Eleven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $171.00.

Johnson & Johnson Price Performance

Shares of JNJ opened at $155.38 on Wednesday. The company has a market cap of $373.86 billion, a price-to-earnings ratio of 17.28, a price-to-earnings-growth ratio of 2.14 and a beta of 0.41. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The company has a 50 day moving average of $153.80 and a two-hundred day moving average of $154.64.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. As a group, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.